Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020)
Scholar Rock Holding's quarterly Non-Current Deffered Revenue came in at $33.2 million in Q4 2020, down 28.6% year-on-year from $46.5 million in Q1 2020, and down 14.32% quarter-over-quarter from $38.7 million in Q3 2020.
Scholar Rock Holding has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $33.2 million in Q4 2020.
- For the quarter ending Q4 2020, Non-Current Deffered Revenue fell 28.6% year-over-year to $33.2 million; the trailing twelve-month figure through Dec 2020 stood at $33.2 million (down 28.6% YoY), and the FY2020 full-year result was $33.2 million, down 28.6% from the prior year.
- Non-Current Deffered Revenue for Q4 2020 stood at $33.2 million, down from $38.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $46.5 million in Q4 2019, with the low at $468000.0 in Q4 2017.
- Average Non-Current Deffered Revenue over 4 years is $28.6 million, with a median of $33.8 million recorded in 2019.
- Year-over-year, Non-Current Deffered Revenue soared 9022.86% in 2018 and slipped 28.6% in 2020.
- Tracing SRRK's Non-Current Deffered Revenue over 4 years: stood at $468000.0 in 2017, then soared by 9022.86% to $42.7 million in 2018, then advanced by 8.89% to $46.5 million in 2019, then fell by 28.6% to $33.2 million in 2020.
- The last three Non-Current Deffered Revenue figures came in at $33.2 million (Q4 2020), $38.7 million (Q3 2020), and $38.1 million (Q2 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 33.19 Mn |
| Sep 30, 2020 | 38.74 Mn |
| Jun 30, 2020 | 38.12 Mn |
| Mar 31, 2020 | 46.11 Mn |
| Dec 31, 2019 | 46.49 Mn |
| Sep 30, 2019 | 29.73 Mn |
| Jun 30, 2019 | 31.24 Mn |
| Mar 31, 2019 | 34.43 Mn |
| Dec 31, 2018 | 42.70 Mn |
| Sep 30, 2018 | 886,000.00 |
| Jun 30, 2018 | 681,000.00 |
| Dec 31, 2017 | 468,000.00 |